Sign Out
CAVSAMIR is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.
CAVSAMIR is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.
CAVSAMIR should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
